NEW YORK, NY, USA I April 26, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational ...

TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest ...

HONG KONG, China I April 24, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) ...

BOSTON, MA, USA I April 25, 2025 I Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful ...

PASADENA, CA, USA I April 26, 2025 I GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that ...

SANDWICH, UK I April 26, 2025 I Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is ...

PRINCETON, NJ, USA I April 26, 2025 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events ...

Data demonstrate potential superiority of antibody-based T cell engager CDR404 over TCR-based approaches, consistent with emerging Phase 1 trial signals of ...

CHENGDU, China I April 25, 2025 I Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted ...

EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiplesolid tumors -- ...

NEWCASTLE, UK I April 25, 2025 I Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three posters ...